Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.44 |
| ▸ | GABRD | O14764 | 2/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.44 |
| ▸ | GABRE | P78334 | 2/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.44 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28319563 | 1.00 | GABRP (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3108329 | 0.77 | — | — | |
| SCHEMBL5532569 | 0.77 | GABRP (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5319389 | 0.77 | — | — | |
| SCHEMBL4791765 | 0.74 | — | — | |
| SCHEMBL6064000 | 0.72 | — | — | |
| SCHEMBL28638529 | 0.72 | GABRP (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL22578897 | 0.72 | — | — | |
| SCHEMBL3320981 | 0.72 | — | — | |
| SCHEMBL11218751 | 0.71 | GABRP (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150196585-A1 | COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS AND USES THEREOF | VIFOR (INTERNATIONAL) LTD. (CH) | 2015-07-16 | — | — | US | disclosed |
| US-20150183908-A1 | COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS AND USES THEREOF | VIFOR (INTERNATIONAL) LTD. (CH) | 2015-07-02 | — | — | US | disclosed |
| EP-2874633-A1 | COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS | Relypsa, Inc. (US) | 2015-05-27 | — | — | EP | disclosed |
| WO-2014015240-A1 | COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS | SORBENT THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
| WO-2014015244-A1 | COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS | SORBENT THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183908-A1 | COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS AND USES THEREOF | PICALM, ORAI1, KCNN3 | GABRP 43/4885GABRD 246/4885GABRA1 127/4885 |
| US-20150196585-A1 | COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS AND USES THEREOF | SSB, PARG, HLA-DRB1 | GABRP 133/4885GABRD 920/4885GABRA1 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.